Literature DB >> 12978309

TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.

.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1952        PMID： 12978309      PMCID： PMC2021603     

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  8 in total

1.  Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro.

Authors:  G MIDDLEBROOK
Journal:  Am Rev Tuberc       Date:  1952-06

2.  Demonstration of increased drug resistance of tubercle bacilli from patients treated with hydrazines of isonicotinic acid.

Authors:  W STEENKEN; G M MEADE; E WOLINSKY; E O COATES
Journal:  Am Rev Tuberc       Date:  1952-06

3.  In vitro studies on isonicotinic acid hydrazide.

Authors:  F PANSY; H STANDER; R DONOVICK
Journal:  Am Rev Tuberc       Date:  1952-06

4.  Resistance to isonicotinic acid hydrazide.

Authors:  G L HOBBY; T F LENERT
Journal:  Am Rev Tuberc       Date:  1952-06

5.  Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid; preliminary report of representative cases.

Authors:  E H ROBITZEK; I J SELIKOFF; G G ORNSTEIN
Journal:  Q Bull Sea View Hosp       Date:  1952-01

6.  Studies on the activity of hydrazine derivatives of isonicotinic acid in the experimental tuberculosis of mice.

Authors:  E GRUNBERG; R J SCHNITZER
Journal:  Q Bull Sea View Hosp       Date:  1952-01

7.  Relation between in-vitro and in-vivo resistance to isoniazid.

Authors:  R GOULDING; M B KING; R KNOX; J M ROBSON
Journal:  Lancet       Date:  1952-07-12       Impact factor: 79.321

8.  Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds.

Authors:  J BERNSTEIN; W A LOTT; B A STEINBERG; H L YALE
Journal:  Am Rev Tuberc       Date:  1952-04
  8 in total
  14 in total

1.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

Review 2.  Do CD1-restricted T cells contribute to antibody-mediated immunity against Mycobacterium tuberculosis?

Authors:  Mark L Lang; Aharona Glatman-Freedman
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

3.  Converting cancer therapies into cures: lessons from infectious diseases.

Authors:  Michael S Glickman; Charles L Sawyers
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

4.  Antituberculous therapy in children.

Authors:  V Seth
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

Review 5.  The chemotherapy of tuberculosis: past, present and future.

Authors:  D Mitchison; G Davies
Journal:  Int J Tuberc Lung Dis       Date:  2012-06       Impact factor: 2.373

Review 6.  Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis.

Authors:  Nicholas D Walter; Michael Strong; Robert Belknap; Diane J Ordway; Charles L Daley; Edward D Chan
Journal:  Respirology       Date:  2012-07       Impact factor: 6.424

7.  Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.

Authors:  Amber Kunkel; Forrest W Crawford; James Shepherd; Ted Cohen
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

Review 8.  Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.

Authors:  Daniel E Goldberg; Robert F Siliciano; William R Jacobs
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

9.  The use of anti-tuberculosis therapy for latent TB infection.

Authors:  Justin T Denholm; Emma S McBryde
Journal:  Infect Drug Resist       Date:  2010-07-21       Impact factor: 4.003

Review 10.  Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.

Authors:  A Glatman-Freedman; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.